Thomas Wiegel

Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer

Farastuk Bozorgmehr, Inn Chung, Rouven Behnisch, Fabian Weykamp et autres

Importance: Chemoimmunotherapy followed by immunotherapy maintenance is the standard first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), yet data regarding efficacy and safety of consolidative thoracic radiotherapy (TRT) are lacking. Objective: To determine whether combining consolidative TRT with immunotherapy maintenance in …

de, us, at (code pays fourni par la source)

Acute Adverse Events of Hypofractionated Whole-Breast Radiation Therapy With a Simultaneous Integrated Boost—Results From the Randomized Controlled HYPOSIB-Trial (ARO 2013-05)

David A. Krug, Reinhard Vonthein, Andreas Schreiber, Alexander D. Boicev et autres

PURPOSE: Moderate hypofractionation is standard of care for adjuvant whole-breast irradiation after breast-conserving surgery. Although boost irradiation has traditionally been administered sequentially after whole-breast irradiation, a growing amount of data suggests that delivery of a simultaneous integrated boost (SIB) may be equally …

de (code pays fourni par la source)

PSA persistence in the PSMA PET era: reassessing a risk factor after radical prostatectomy

Sophia Scharl, Reinhard Thamm, Constantinos Zamboglou, Iosif Strouthos et autres

BACKGROUND AND PURPOSE: The association of prostate-specific antigen (PSA) persistence after radical prostatectomy (RP) with inferior prognosis was demonstrated in a systematic review. However, all patients in the included studies lacked a prostate-specific membrane antigen Positron-Emissions-Tomography (PSMA-PET) before salvage radiotherapy (SRT). Since …

de, it, ch, au (code pays fourni par la source)

PSA persistence in the PSMA PET era: reassessing a risk factor after radical prostatectomy.

Sophia Scharl, Reinhard Thamm, Constantinos Zamboglou, Iosif Strouthos et autres

Background And Purpose The association of prostate-specific antigen (PSA) persistence after radical prostatectomy (RP) with inferior prognosis was demonstrated in a systematic review. However, all patients in the included studies lacked a prostate-specific membrane antigen Positron-Emissions-Tomography (PSMA-PET) before salvage radiotherapy (SRT). Since …

at, us (code pays fourni par la source)

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update: Treatment of Relapsing and Metastatic Prostate Cancer.

Derya Tilki, Roderick C.N. van den Bergh, Erik Briers, Peter Chiu et autres

Background and objective To present a summary of the 2026 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy & Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric …

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.

Philip Cornford, Roderick C.N. van den Bergh, Erik Briers, Peter Chiu et autres

Background and objective To present a summary of the 2026 version of the European Association of Urology (EAU)–European Association of Nuclear Medicine (EANM)–European Society for Radiotherapy and Oncology (ESTRO)–European Society of Urogenital Radiology (ESUR)–International Society of Urological Pathology (ISUP)–International Society of Geriatric …

ie, ch, fr, be, it, gr, gb, es, no, nl, us, au, se, de, tr (code pays fourni par la source)

First clinical application of silicon-based [¹⁸F]siPSMA-14 in prostate cancer patients: A proof-of-concept study

Jonathan Miksch, Elham Yousefzadeh‐Nowshahr, Deni Hardiansyah, Gerhard Glatting et autres

Silicon-based ligands are of interest in increasingly used Prostate-specific membrane antigen (PSMA) tracers for prostate cancer (PCa) staging due to their simple and scalable production. Here, we present first data on dosimetry and biodistribution of the novel PSMA-specific tracer [¹⁸F]siPSMA-14.Seven PCa patients …

de, id, us (code pays fourni par la source)

Refining prognostic stratification in salvage radiotherapy for prostate cancer: a retrospective multicenter cohort study using PSMA-PET and machine learning

Federica Medici, Daniel M. Aebersold, Jozefina Casuscelli, Louise Emmett et autres

BACKGROUND: Salvage radiotherapy (SRT) is the standard treatment for biochemical recurrence (bREC) after radical prostatectomy (RP), yet optimal radiation dose, field size, and the role of advanced imaging like PSMA-PET remain unclear. This study assessed the impact of SRT dose and the …

fr, it, ch, de, au, cy, us (code pays fourni par la source)

Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415)

Farastuk Bozorgmehr, Inn Chung, Jürgen R. Fischer, Marc Bischof et autres

Introduction of immune checkpoint inhibitors (ICI) has improved overall survival (OS) for advanced non-small cell lung cancer (NSCLC). However, responses differ greatly amongst patients. Additional radiotherapy (RT) may promote tumor-specific immunity and synergize with ICI to improve tumor control. The multicenter phase …

de (code pays fourni par la source)

The early detection, diagnostic evaluation, and local treatment of prostate cancer: A paradigm shift

Peter Albers, Tobias Franiel, Thomas Kötter, Glen Kristiansen et autres

BACKGROUND: Approximately 75 000 men receive a diagnosis of prostate cancer in Germany each year. New data on the early detection, diagnostic evaluation, and treatment of prostate cancer provide the basis for a paradigm shift in the management of locally confined prostate …

de (code pays fourni par la source)

Salvage-Strahlentherapie nach radikaler Prostatektomie

Reinhard Thamm, Angelika Borkowetz, Thomas Wiegel

de (code pays fourni par la source)

110 | HIGH PFS WITH LOW INFIELD RECURRENCES AFTER LOW DOSE RADIOTHERAPY AND OBINUTUZUMAB IN EARLY STAGE NODAL FOLLICULAR LYMPHOMA: FINAL RESULTS OF THE GAZAI STUDY (GLA 2018‐3)

Klaus K Herfarth, Christian Wilfried Scholz, Kai Hübel, Stefan Wirths et autres

de, it (code pays fourni par la source)